1

Group 150

05.27.2020

Related Articles

Value-Based Pricing of New Technologies

What is value-based pricing? Value-based pricing aims to reward pharmaceutical companies and medical device companies for investments in new healthcare technologies that result in sustained improvements in patient quality of life. We also expect such technologies to deliver measurable net economic benefits for society. In economic theory, value-based pricing is when a buyer’s willingness to […]

Read all
Budget Impact Analysis

What is Budget Impact Analysis? Pharmacoeconomic analyses in healthcare are paramount, because of the high costs of innovative technologies and limited possibilities of their funding. Budget Impact Analysis (BIA) is one such analysis that provides vital information for healthcare decision makers [1].  Unlike economic evaluations, such as cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit […]

Read all
Global Pharma Market Access: Pharmacoeconomics in Middle-income Countries

Many middle-income countries such as Egypt, South Africa, Malaysia, Thailand, and Brazil have pharmacoeconomic guidelines. These follow the recommendations by the International Society for Pharmacoeconomics and Outcomes Research but include country-specific differences. The variations respond to changes in how governments apply pharmacoeconomics and determine market access to pharmaceuticals and medical devices. This is also determined […]

Read all
Read all articles